Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04729686 · ClinicalTrials.gov registry record · Phase 4

The Pericapsular Nerve Block in Total Hip Arthroplasty

A Phase 4 study of Hip Osteoarthritis and Hip Arthropathy, sponsored by LifeBridge Health.

Recruiting
Registry status
Phase 4
Development phase
78
Enrollment target
1
Study location

NCT04729686 is a Phase 4 study of Hip Osteoarthritis and Hip Arthropathy that is actively recruiting participants, run by LifeBridge Health. The registered enrollment target is 78 participants, below the 398-participant average among 11 other Hip Osteoarthritis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04729686, a Phase 4 study of Hip Osteoarthritis and Hip Arthropathy, is actively recruiting participants, sponsored by LifeBridge Health.

RECRUITING
Registry status
Phase 4
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

In order to continue progressing towards outpatient total hip arthroplasty (THA), methods to adequately manage postoperative pain is of paramount importance. The purpose of this study is to quantify the effectiveness of the pericapsular nerve block in total hip arthroplasty in comparison to the fascia iliaca nerve block.

Interventions

  • DRUG Pericapsular Nerve Block
  • DRUG Fascia Iliaca Nerve Block

Study Locations (1)

Maryland

  • Sinai Hospital of Baltimore - Baltimore

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2020-12-09
Est. Completion 2025-12-01
Phase Phase 4

Sponsor

LifeBridge Health

14 total trials

What the Registry Record Tells You About NCT04729686

The ClinicalTrials.gov registry entry for NCT04729686 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 398-participant average among 11 other Hip Osteoarthritis trials with a reported enrollment target (80% lower). The listed sponsor is LifeBridge Health, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hip Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Pericapsular Nerve Block is the first listed.

NCT04729686 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04729686 about?

NCT04729686 is a clinical study titled "The Pericapsular Nerve Block in Total Hip Arthroplasty". In order to continue progressing towards outpatient total hip arthroplasty (THA), methods to adequately manage postoperative pain is of paramount importance. The purpose of this study is to quantify the effectiveness of the pericapsular nerve block in total hip arthroplasty in comparison to the fasc...

What is the current status of trial NCT04729686?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2020-12-09. Estimated completion is 2025-12-01.

What conditions does trial NCT04729686 study?

This clinical trial studies the following conditions: Hip Osteoarthritis, Hip Arthropathy.

What interventions are being tested in trial NCT04729686?

The interventions under investigation include: Pericapsular Nerve Block (DRUG), Fascia Iliaca Nerve Block (DRUG).

Who is sponsoring clinical trial NCT04729686?

This trial is sponsored by LifeBridge Health, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04729686 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hip Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.